|
End-of-day quote
Taipei Exchange
2026-08-12
|
5-day change | 1st Jan Change | ||
| 7.350 TWD | +2.08% |
|
+2.08% | -25.76% |
| 04-28 | Pharmigene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 25-08-11 | Pharmigene, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
Company Valuation: Pharmigene, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,087 | 943.2 | 862.8 | 1,045 | 719.1 | 499.6 |
| Change | - | -13.2% | -8.53% | 21.08% | -31.16% | -30.53% |
| Enterprise Value (EV) 1 | 810.8 | 718.8 | 676.6 | 1,455 | 1,177 | 1,069 |
| Change | - | -11.34% | -5.87% | 115.03% | -19.11% | -9.16% |
| P/E | -75.5x | -40.2x | -20.2x | -13x | -8.68x | -6.84x |
| PBR | 2.65x | 2.47x | 2.54x | 2.35x | 2.06x | 1.79x |
| PEG | - | -0.6x | -0.2x | -0.2x | -3.1x | 0.6x |
| Capitalization / Revenue | 10.7x | 7.29x | 6.45x | 7.87x | 6.17x | 2.5x |
| EV / Revenue | 8x | 5.56x | 5.06x | 11x | 10.1x | 5.35x |
| EV / EBITDA | -92.8x | -49.1x | -21.4x | -33.7x | -18x | -31.3x |
| EV / EBIT | -58.5x | -31.6x | -15.2x | -24.6x | -13.8x | -19.5x |
| EV / FCF | -44.1x | -29.5x | -34.6x | -2.02x | -12.2x | -20.7x |
| FCF Yield | -2.27% | -3.39% | -2.89% | -49.5% | -8.22% | -4.82% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.3312 | -0.54 | -0.9828 | -1.597 | -1.642 | -1.446 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 101.4 | 129.4 | 133.8 | 132.7 | 116.5 | 199.9 |
| EBITDA 1 | -8.735 | -14.63 | -31.67 | -43.19 | -65.21 | -34.16 |
| EBIT 1 | -13.87 | -22.74 | -44.45 | -59.18 | -85.22 | -54.96 |
| Net income 1 | -11.21 | -23.43 | -42.72 | -72.65 | -82.86 | -73 |
| Net Debt 1 | -275.8 | -224.3 | -186.2 | 410.3 | 457.8 | 569.6 |
| Reference price 2 | 25.000 | 21.700 | 19.850 | 20.700 | 14.250 | 9.900 |
| Nbr of stocks (in thousands) | 43,465 | 43,465 | 43,465 | 50,465 | 50,465 | 50,465 |
| Announcement Date | 4/26/21 | 5/19/22 | 4/6/23 | 4/30/24 | 3/13/25 | 4/28/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 11.5M | |
| -46.36x | 13.34x | 857.49x | -.--% | 4.03B | |
| 40.3x | 5.16x | 18.93x | -.--% | 3.59B | |
| -13.93x | 7.2x | -13.07x | -.--% | 3.05B | |
| 22.15x | - | - | - | 2.45B | |
| 16.46x | 2.02x | 7.06x | 3.6% | 1.03B | |
| -18.8x | 4.07x | 25.48x | -.--% | 861M | |
| Average | -0.03x | 6.36x | 179.18x | 0.72% | 2.15B | |
| Weighted average by Cap. | -1.97x | 7.95x | 279.61x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 7595 Stock
- Valuation Pharmigene, Inc.
Select your edition
All financial news and data tailored to specific country editions
